Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporin A plus acitretin versus acitretin alone for moderate-to-severe psoriasis
ChiCTR-OPN-17013383Phase 4Recruiting
- Sponsor
- Hospital for Skin Diseases, Chinese Academy of Medical Sciences
- Start
- Nov 2017
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cyclosporine and acitretin in psoriasis (2 arms), sponsored by Hospital for Skin Diseases, Chinese Academy of Medical Sciences. Primary endpoint: Psoriasis Area and Severity Index at 24 weeks. Started Nov 2017; status: recruiting.
02
Drugs
cyclosporineacitretin
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR-OPN-17013383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17013383.